Human Insulin Market Overview
Globally, demand for human insulin has increased mostly due to rising rates of diabetes and obesity, which are caused by changing lifestyles and excessive sugar consumption in a variety of foods and beverages. These primary factors have enhanced the global human insulin market by increasing the demand for human insulin. Additionally, the market has benefited from increasing investments in research and development activities by numerous organizations that have simplified the method insulin is injected. The global market for human insulin is being driven by the introduction of safety pen needles and pen devices for effective insulin delivery. Furthermore, rising diabetes awareness has fueled demand in the human insulin industry.
With the expanding need for human insulin, this market offers a variety of opportunities, including the implementation of rules to combat needle anxiety, needle stick injuries, and increased awareness of the dangers of blood-borne disease transmission. Furthermore, the rising demand for biosimilar pharmaceuticals, which are less expensive, is one of the key growth factors for the global human insulin market.
However, in emerging markets, restricted access to human insulin and inconsistent pricing may hinder market expansion. Nonetheless, the government's and other organizations' increasing efforts in the healthcare sector may help in overcoming these restrictions.
| Report Metric | Details |
| Market size available for years | 2023–2030 |
| Base year considered | 2023 |
| Forecast period | 2024–2030 |
| Forecast unit | Value (USD Million) |
| Segments covered | Types, Brand, and Region. |
| Regions covered | North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA) |
| Companies covered | Novo Nordisk A/S, Eli Lilly and Company, Tonghua Dongbao Pharmaceutical Co., Adocia, Merck & Co., Inc., Sanofi, Biocon, Ltd., Wockhardt. |
Covid-19 Impact on Human Insulin Market
In addition, the current Human Insulin Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Human Insulin Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Human Insulin Market Segment Overview
According to Types, Modern Human Insulin is one of the largest segments in the global Human Insulin market. Premixed Modern and Long Acting are the fastest-growing categories of this segment. Based on the Brands, Modern Human Insulin Brands is another major segment in the market. Humalog, Novomix, Novorapid, Lantus, Levemir, and Apidra are examples of modern brands. In comparison to branded drugs, biosimilars have gained popularity in recent years. In the Asia-Pacific area, biosimilars such as Basalog, Wosulin, and Glaritus are available. Lantus has the biggest market share among traditional and modern brands, while Levemir and Apidra are the fastest-growing insulin drugs.
Human Insulin Market, By Types
- Traditional Human Insulin
- Premixed Traditional
- Intermediate Acting
- Short Acting
- Modern Human Insulin
- Premixed Modern
- Long Acting
- Rapid Acting
Human Insulin Market, By Brand
- Traditional Human Insulin Brands
- Humulin
- Actrapid
- Insuman
- Modern Human Insulin Brands
- Humalog
- Novomix
- Novorapid
- Lantus
- Levemir
- Apidra
Human Insulin Market Regional Overview
Geographically, the global human insulin market is expected to be dominated by North America during the forecast period. The rise of the human insulin market in this region is being attributed to the rising incidence of diabetes and the growing geriatric population. Several European nations, such as France, Germany, and Italy, are expected to contribute significantly to revenue growth in the human insulin market over the forecast period. Meanwhile, Asia Pacific is expected to be one of the most promising areas for human insulin growth. The area has been advantageous for the growth of the human insulin market as a result of increasing research and development initiatives by various organizations and growing government initiatives.
Human Insulin Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Human Insulin Market, Key Players
· Novo Nordisk A/S
· Eli Lilly and Company
· Tonghua Dongbao Pharmaceutical Co.
· Adocia
· Merck & Co., Inc.
· Sanofi
· Biocon, Ltd.
· Wockhardt
Frequently Asked Questions (FAQ) :
Q1. What are the driving factors for the global Human Insulin market?
Globally, demand for human insulin has increased mostly due to rising rates of diabetes and obesity, which are caused by changing lifestyles and excessive sugar consumption in a variety of foods and beverages.
Q2. What are the restraining factors for the global Human Insulin market?
In emerging markets, restricted access to human insulin and inconsistent pricing may hinder market expansion.
Q3. Which segment is projected to hold the largest share in the global Human Insulin market?
Modern Human Insulin segment is projected to hold the largest share in the global Human Insulin market.
Q4. Which region holds the largest share in the global Human Insulin market?
North America held the largest share in the global Human Insulin market.
Q5. Which are the prominent players in the global Human Insulin market?
Novo Nordisk A/S, Eli Lilly and Company, Tonghua Dongbao Pharmaceutical Co., Adocia, Merck & Co., Inc., Sanofi, Biocon, Ltd., Wockhardt. are some key players in the global Human Insulin market.
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Human Insulin Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Types
- 5.2.1. Traditional Human Insulin
- 5.2.1.1. Premixed Traditional
- 5.2.1.2. Intermediate Acting
- 5.2.1.3. Short Acting
- 5.2.2. Modern Human Insulin
- 5.2.2.1. Premixed Modern
- 5.2.2.2. Long Acting
- 5.2.2.3. Rapid Acting
- 5.2.1. Traditional Human Insulin
- 5.3.1. Traditional Human Insulin Brands
- 5.3.1.1. Humulin
- 5.3.1.2. Actrapid
- 5.3.1.3. Insuman
- 5.3.2. Modern Human Insulin Brands
- 5.3.2.1. Humalog
- 5.3.2.2. Novomix
- 5.3.2.3. Novorapid
- 5.3.2.4. Lantus
- 5.3.2.5. Levemir
- 5.3.2.6. Apidra
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America, Middle East and Africa
6. North America Human Insulin Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Types
- 6.2.1. Traditional Human Insulin
- 6.2.1.1. Premixed Traditional
- 6.2.1.2. Intermediate Acting
- 6.2.1.3. Short Acting
- 6.2.2. Modern Human Insulin
- 6.2.2.1. Premixed Modern
- 6.2.2.2. Long Acting
- 6.2.2.3. Rapid Acting
- 6.2.1. Traditional Human Insulin
- 6.3.1. Traditional Human Insulin Brands
- 6.3.1.1. Humulin
- 6.3.1.2. Actrapid
- 6.3.1.3. Insuman
- 6.3.2. Modern Human Insulin Brands
- 6.3.2.1. Humalog
- 6.3.2.2. Novomix
- 6.3.2.3. Novorapid
- 6.3.2.4. Lantus
- 6.3.2.5. Levemir
- 6.3.2.6. Apidra
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Human Insulin Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Types
- 7.2.1. Traditional Human Insulin
- 7.2.1.1. Premixed Traditional
- 7.2.1.2. Intermediate Acting
- 7.2.1.3. Short Acting
- 7.2.2. Modern Human Insulin
- 7.2.2.1. Premixed Modern
- 7.2.2.2. Long Acting
- 7.2.2.3. Rapid Acting
- 7.2.1. Traditional Human Insulin
- 7.3.1. Traditional Human Insulin Brands
- 7.3.1.1. Humulin
- 7.3.1.2. Actrapid
- 7.3.1.3. Insuman
- 7.3.2. Modern Human Insulin Brands
- 7.3.2.1. Humalog
- 7.3.2.2. Novomix
- 7.3.2.3. Novorapid
- 7.3.2.4. Lantus
- 7.3.2.5. Levemir
- 7.3.2.6. Apidra
- 7.4.1. UK
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Russia
- 7.4.7. Rest of Europe
8. Asia Pacific Human Insulin Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Types
- 8.2.1. Traditional Human Insulin
- 8.2.1.1. Premixed Traditional
- 8.2.1.2. Intermediate Acting
- 8.2.1.3. Short Acting
- 8.2.2. Modern Human Insulin
- 8.2.2.1. Premixed Modern
- 8.2.2.2. Long Acting
- 8.2.2.3. Rapid Acting
- 8.2.1. Traditional Human Insulin
- 8.3.1. Traditional Human Insulin Brands
- 8.3.1.1. Humulin
- 8.3.1.2. Actrapid
- 8.3.1.3. Insuman
- 8.3.2. Modern Human Insulin Brands
- 8.3.2.1. Humalog
- 8.3.2.2. Novomix
- 8.3.2.3. Novorapid
- 8.3.2.4. Lantus
- 8.3.2.5. Levemir
- 8.3.2.6. Apidra
- 8.4.1. China
- 8.4.2. India
- 8.4.3. Japan
- 8.4.4. Australia
- 8.4.5. South East Asia
- 8.4.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Human Insulin Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Types
- 9.2.1. Traditional Human Insulin
- 9.2.1.1. Premixed Traditional
- 9.2.1.2. Intermediate Acting
- 9.2.1.3. Short Acting
- 9.2.2. Modern Human Insulin
- 9.2.2.1. Premixed Modern
- 9.2.2.2. Long Acting
- 9.2.2.3. Rapid Acting
- 9.2.1. Traditional Human Insulin
- 9.3.1. Traditional Human Insulin Brands
- 9.3.1.1. Humulin
- 9.3.1.2. Actrapid
- 9.3.1.3. Insuman
- 9.3.2. Modern Human Insulin Brands
- 9.3.2.1. Humalog
- 9.3.2.2. Novomix
- 9.3.2.3. Novorapid
- 9.3.2.4. Lantus
- 9.3.2.5. Levemir
- 9.3.2.6. Apidra
- 9.4.1. Brazil
- 9.4.2. Saudi Arabia
- 9.4.3. UAE
- 9.4.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. Novo Nordisk A/S
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. Eli Lilly and Company
- 10.6. Tonghua Dongbao Pharmaceutical Co.
- 10.7. Adocia
- 10.8. Merck & Co., Inc.
- 10.9. Sanofi
- 10.10. Biocon, Ltd.
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
